BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 20494930)

  • 1. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.
    Thol F; Weissinger EM; Krauter J; Wagner K; Damm F; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Haematologica; 2010 Oct; 95(10):1668-74. PubMed ID: 20494930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    Ann Hematol; 2012 Apr; 91(4):519-25. PubMed ID: 21997850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
    Wang N; Wang F; Shan N; Sui X; Xu H
    Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutations in acute myeloid leukemia.
    Rakheja D; Konoplev S; Medeiros LJ; Chen W
    Hum Pathol; 2012 Oct; 43(10):1541-51. PubMed ID: 22917530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
    Tong HY; Hu C; Yu MX; Ma QL; Chen FF; Ye L; Wei JY; Xu GX; Mao LP; Li Y; Jin J
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(40):3180-4. PubMed ID: 24405536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
    Bill M; Jentzsch M; Bischof L; Kohlschmidt J; Grimm J; Schmalbrock LK; Backhaus D; Brauer D; Goldmann K; Franke GN; Vucinic V; Niederwieser D; Mims AS; Platzbecker U; Eisfeld AK; Schwind S
    Blood Adv; 2023 Feb; 7(3):436-444. PubMed ID: 35381077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
    Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
    Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase mutations in myeloid malignancies.
    Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
    Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
    Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
    Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia.
    Chou WC; Lei WC; Ko BS; Hou HA; Chen CY; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
    Leukemia; 2011 Feb; 25(2):246-53. PubMed ID: 21079611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.
    Patnaik MM; Hanson CA; Hodnefield JM; Lasho TL; Finke CM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
    Leukemia; 2012 Jan; 26(1):101-5. PubMed ID: 22033490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Platt MY; Fathi AT; Borger DR; Brunner AM; Hasserjian RP; Balaj L; Lum A; Yip S; Dias-Santagata D; Zheng Z; Le LP; Graubert TA; Iafrate AJ; Nardi V
    J Mol Diagn; 2015 Nov; 17(6):661-8. PubMed ID: 26331834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
    Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU
    Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.
    Molenaar RJ; Thota S; Nagata Y; Patel B; Clemente M; Przychodzen B; Hirsh C; Viny AD; Hosano N; Bleeker FE; Meggendorfer M; Alpermann T; Shiraishi Y; Chiba K; Tanaka H; van Noorden CJ; Radivoyevitch T; Carraway HE; Makishima H; Miyano S; Sekeres MA; Ogawa S; Haferlach T; Maciejewski JP
    Leukemia; 2015 Nov; 29(11):2134-42. PubMed ID: 25836588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent
    Ok CY; Loghavi S; Sui D; Wei P; Kanagal-Shamanna R; Yin CC; Zuo Z; Routbort MJ; Tang G; Tang Z; Jorgensen JL; Luthra R; Ravandi F; Kantarjian HM; DiNardo CD; Medeiros LJ; Wang SA; Patel KP
    Haematologica; 2019 Feb; 104(2):305-311. PubMed ID: 30171025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
    Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
    Thol F; Damm F; Wagner K; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Heil G; Heuser M; Krauter J; Ganser A
    Blood; 2010 Jul; 116(4):614-6. PubMed ID: 20421455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.
    Patel KP; Barkoh BA; Chen Z; Ma D; Reddy N; Medeiros LJ; Luthra R
    J Mol Diagn; 2011 Nov; 13(6):678-86. PubMed ID: 21889610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.